Report on the Thyroid Ultrasound Examination (TUE) Full-Scale Survey (the fourth-round survey)

As of June 30, 2022

1. Summary

1.1 Purpose

In order to monitor the long-term health of children, we conducted another Full-Scale Survey (the fourthround survey), following the Preliminary Baseline Survey for background assessment of thyroid glands, and two Full-Scale Surveys (the second- and third-round surveys) to continuously monitor thyroid gland status.

1.2 Eligible Persons

All residents in Fukushima 18 years old and younger at the time of the Earthquake (all those residents who were born between April 2, 1992 and April 1, 2012)

1.3 Implementation Period

FY2018 and FY2019, starting in April 2018:

1.3-1 For those 18 years old or younger

The examination will be carried out on a municipality-by-municipality basis in FY2018 and FY2019.

1.3-2 For those 19 years old or older

The examination will be carried out on an age group basis (i.e., school grade)

In FY2018: those born in FY1996 and FY1998

In FY2019: those born in FY1997 and FY1999

1.3-3 For those 25 years old and older

For those who are older than 20 years, it is recommend to take TUE every 5 years at ages that are multiples of 5 (i.e., 25, 30, \dots)

In FY2018: those born in FY1993

In FY2019: those born in FY1994

1.4 Responsible Organizations and Implementing Medical Facilities and Institutions (as of June 30, 2022)

The Fukushima Prefectural Government entrusts Fukushima Medical University (FMU) to conduct the Survey. For the convenience of participants, FMU has Agreements of Cooperation with medical institutions and facilities outside of Fukushima prefecture.

1.4-1 Primary examination facilities

Within Fukushima Prefecture	85 medical facilities and institutions
Other Prefectures	130 medical facilities and institutions
1.4-2 Confirmatory examination facili	ties

Within Fukushima Prefecture5 medical facilities and institutions including FMUOther Prefectures37 medical facilities and institutions

1.5 Methods

1.5-1 Primary examination

Ultrasonography of the thyroid gland

Assessments are made by specialists based on the following criteria:

- Grade A
 - A1: No nodules/cysts

A2: Nodules ≤ 5.0 mm and/or cysts ≤ 20.0 mm

- Grade B

Nodules \geq 5.1 mm and/or cysts \geq 20.1 mm

Some A2 results may be re-classified as B results when clinically indicated.

- Grade C


Prompt confirmatory examination warranted, based on the judgement of initial results.

1.5-2 Confirmatory examination

The examination includes ultrasonography of the thyroid gland, blood and urine tests for those with Grade B or C results, and if necessary, additional Fine Needle Aspiration Cytology (FNAC) will be performed.

Priority is given to those in urgent clinical need. A medical follow-up may be recommended based on the confirmatory examination results.


1.5-3 Thyroid Examination Flow chart





1.6 Municipalities Surveyed

The municipalities where examinations (for those 18 years old or younger) were carried out in FY2018 and FY2019 are as follows:



Note: Primary examinations that had been scheduled in March 2020 at elementary and junior high schools in Iwaki City were postponed due to the COVID-19 pandemic. These examinations were rescheduled and carried out in September and October of 2020.

Fig.2 Municipalities surveyed in FY2018 and FY2019

2 Results as of June 30, 2022

2-1 Results of the Primary Examination

2.1-1 Implementation Status

The examination was carried out for 183,410 (62.3%) participants by June 30, 2022.

(Implementation status for each municipality and prefectures other than Fukushima are shown in Appendix 1 and Appendix 2.)

Results of 183,410 participants (100.0%) have been finalized and individual result reports were sent out. (The result for each municipality is shown in Appendix 3.)

Of these, 61,712 (33.6%) had Grade A1 results, 120,304 (65.6%) had Grade A2, 1,394 (0.8%) had Grade B, and none had Grade C.

		Parti	icipants(%)			Participants with finalized results(%)							
	Eligible Persons	Other							A			ose refe firmato		
				pretecture			A	1	A2		В			С
	а	b	(b/a)		С	(c/b)	d	(d/c)	е	(e/c)	f	(f/c)	g	(g/c)
FY2018	168,023	108,002	(64.3)	7,233	108,002	(100.0)	36,895	(34.2)	70,401	(65.2)	706	(0.7)	C	0 (0.0)
FY2019	126,205	75,408	(59.8)	3,001	75,408	(100.0)	24,817	(32.9)	49,903	(66.2)	688	(0.9)	C	0 (0.0)
Total	294,228	183,410	(62.3)	10,234	183,410	(100.0)	61,712	(33.6)	120,304	(65.6)	1,394	(0.8)	C	0 (0.0)

Table 1 Progress and results of the primary examination

Table 2 Number and percentage of participants with nodules/cysts

		Participants with nodules / cysts (%)								
	Participants with finalized results	Nodules				Cysts				
		≥5.1ı	mm	≤5.0r	nm	≥20	.1mm	≤20.0mm		
	а	b	(b/a)	с	(c/a)	d	(d/a)	е	(e/a)	
FY2018	108,002	702	(0.6)	369	(3.0)	4	(0.0)	70,758	(65.5)	
FY2019	75,408	687	(0.9)	300	(0.4)	1	(0.0)	50,246	(66.6)	
Total	183,410	1,389	(0.8)	669	(0.4)	5	(0.0)	121,004	(66.0)	

· Percentages are rounded to a lower decimal place. This applies to other tables as well.

• Those born between FY1992 and FY1995 are excluded as they are eligible for the Age 25 Survey. Results for the Age 25 Survey participants will be reported separately.

• Examinations for those born in FY1992 (approx. 23,000), FY1993 (approx. 22,000), FY1994 (approx. 22,000), and FY1995 (approx. 21,000) were carried out in FY2017, FY2018, FY2019, and FY2020, respectively.

2.1-2 Participation rates by age group

Table 3 shows the participation rate for each age group as of April 1 of each year.

			Total		Age Group	
	Age Group			6-11	12-17	18-24
FY2018	Survey population	а	168,023	56,935	64,826	46,262
112010	Participants	b	108,002	49,638	52,673	5,691
	Participation Rate(%)	(b/a)	64.3	87.2	81.3	12.3
	Age Group			7-11	12-17	18-24
FY2019	Survey population	а	126,205	34,206	47,274	44,725
112013	Participants	b	75,408	30,187	39,253	5,968
	Participation Rate(%)	(b/a)	59.8	88.3	83.0	13.3
	Survey population	а	294,228	91,141	112,100	90,987
Total	Participants	b	183,410	79,825	91,926	11,659
	Participation Rate(%)	(b/a)	62.3	87.6	82.0	12.8

Table 3 Participation rates by age group

*Age groups are as of April 1 of each fiscal year.

2.1-3 Comparison of the third- and fourth-round survey results

Table 4 is the comparison chart for the results of two Full-Scale Surveys (third- and fourth-round surveys).

Among 163,681 participants with Grade A1 or A2 results in the third-round survey, 163,002 (99.6%) had Grade A1 or A2 results, and 679 (0.4%) had Grade B results in the fourth-round survey.

Among 732 participants with Grade B results in the third-round survey, 148 (20.2%) had Grade A1 or A2 results, and 584 (79.8%) had Grade B results in the fourth-round survey

			Results of the	Res	ults of the fou	rth-round surve	∋у**
			third-round	I A1			С
			survey*	A1	A2	В	C
			а	b	С	d	е
			(%)	(b/a)	(c/a)	(d/a)	(e/a)
		A1	56,482	42,756	13,619	107	0
	A		(100.0)	(75.7)	(24.1)	(0.2)	(0.0)
		A2	107,199	11,281	95,346	572	0
Results of		AZ	(100.0)	(10.5)	(88.9)	(0.5)	(0.0)
the third-round		3	732	12	136	584	0
survey	L	5	(100.0)	(1.6)	(18.6)	(79.8)	(0.0)
ourroy		2	0	0	0	0	0
		ر ر	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
	Not		18,997	7,663	11,203	131	0
	Participated		(100.0)	(40.3)	(59.0)	(0.7)	(0.0)
Total			183,410	61,712	120,304	1,394	0
TOLAI	Total		(100.0)	(33.6)	(65.6)	(0.8)	(0.0)

Table 4 Comparison of the 3rd and 4th round survey results

* The number for Results of the third-round survey is the number from fourth-round survey participants with finalized results, not the breakdown of all third-round survey participants.

** Results of the fourth-round survey participants who were diagnosed with each grade in the thirdround survey.

2.2 Results of the Confirmatory Examination

2.2-1 Implementation status

By June 30, 2022, 1,036 out of 1,394 people (74.3%) have had the examination. Of those, 1,016 (98.1%) completed the entire process of the confirmatory examination. (Table 5 shows the progress and results of the confirmatory examination.)

Of the aforementioned 1,016 participants, 94 (9.3%) were confirmed to meet Grade A diagnostic criteria by the primary examination standards (A1: 6, A2: 88) (including those with other thyroid disease). The remaining 922 (90.7%) were confirmed to be outside of A1/A2 criteria.

	Those referred to							Those	with final	ized result	s (%)		
	confirmatory	Participants (%)					Not A	1 or A2					
	exams	· · ·	,			A1		~2				FN	٩C
	а	b	(b/a)	С	(c/b)	d	(d/c)	е	(e/c)	f	(f/c)	g	(g/f)
FY2018	706	525	(74.4)	516	(98.3)	3	(0.6)	46	(8.9)	467	(90.5)	48	(10.3)
FY2019	688	511	(74.3)	500	(97.8)	3	(0.6)	42	(8.4)	455	(91.0)	43	(9.5)
Total	1,394	1,036	(74.3)	1,016	(98.1)	6	(0.6)	88	(8.7)	922	(90.7)	91	(9.9)

2.2-2 Results of Fine Needle Aspiration Cytology (FNAC)

Among those who had FNAC, 39 had nodules classified as malignant or suspicious for malignancy: 17 of them were male, and 22 were female.

Participants' age at the time of their confirmatory examination ranged from 9 to 24 years (mean age: 17.0 ± 3.1 years). The minimum and maximum tumor diameters were 6.1 mm and 29.4 mm and mean tumor diameter was 13.1 ± 6.3 mm.


Of those 39 participants, 26 had Grade A results (A1: 6, A2: 20) and 9 had Grade B results in the third-round survey. The remaining 4 participants did not undergo the third-round survey.

Table 6 Results of FNAC

A. Municipalities surveyed in FY 2018	
•Malignant or suspicious for malignancy: 22*)	
• Male to female ratio:	11:11
·Mean age (SD, min-max):	16.9 (3.5, 11-24), 8.5 (3.1, 2-14) at the time of disaster
·Mean tumor size:	11.7 mm (5.1 mm, 6.9-29.4 mm)
B. Municipalities surveyed in FY 2019	
• Malignant or suspicious for malignancy: 17*)	
• Male to female ratio:	6:11
·Mean age (SD, min-max):	17.1 (2.7, 9-20), 8.1 (2.8, 0-12) at the time of disaster
·Mean tumor size:	14.9 mm (7.3 mm, 6.1-29.0 mm)
C. Total	
• Malignant or suspicious for malignancy:39 *)	
• Male to female ratio:	17:22
·Mean age (SD, min-max):	17.0 (3.1, 9-24), 8.3 (2.9, 0-14) at the time of disaster
·Mean tumor size:	13.1 mm (6.3 mm, 6.1-29.4 mm)

*) Appendix 6 shows surgery cases

2.2-3 Age distribution of malignant or suspicious-for-malignancy cases diagnosed by FNAC. Age distributions of 39 people with malignant or suspicious nodules based on their age as of March 11, 2011 is per Fig. 3, and age distribution based on their actual age at the time of confirmatory examination is per Fig. 4.



*Participants who are 15 to 18 years of age excluded from the 4th round survey.
*The age -1 refers to the participants who were born between April 2, 2011 and April 1, 2013. The age 0 includes those who were born between March 12, 2011 and April 1, 2011.




Figure 4: Age distribution as of confirmatory examination

2.2-4 Basic Survey results of those with malignant or suspicious nodules by FNAC.

Of the 39 people with malignant or suspicious nodules, 19 people (48.7%) had responded in the Basic Survey (for external radiation dose estimation), and all 19 received their own results. The highest effective dose documented was 2.4 mSv.

Table 7: Details of estimated doses of Basic Survey responders with malignant or suspicious-formalignancy cases.

				Age	at the tim	ne of disas	ter			
Effective	0	-5	6-1	10	11-	15	16-	18	Total	
dose (mSv)	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
< 1	0	2	3	4	0	0	0	0	3	6
1-1.9	0	0	2	1	2	0	0	0	4	1
2-4.9	2	0	0	2	1	0	0	0	3	2
5-9.9	0	0	0	0	0	0	0	0	0	0
10-19.9	0	0	0	0	0	0	0	0	0	0
≥20	0	0	0	0	0	0	0	0	0	0
Total	2	2	5	7	3	0	0	0	10	9




Figure 5: Effective doses of Basic Survey responders

2.2-5 Blood and urinary iodine test results

	ICSUIIS		Mican ± OD	(percentage outs		
	FT4 ¹⁾ (ng/dL)	FT3 ²⁾ (pg/mL)	TSH ³⁾ (µIU/mL)	Tg ⁴⁾ (ng/mL)	TgAb ⁵⁾ (IU/mL)	TPOAb ⁶⁾ (IU/mL)
Reference Range	0.95-1.74 7)	2.13-4.07 7)	0.340-3.880 7)	≥33.7	< 28.0	< 16.0
Malignant or suspicious 39 participants	1.3±0.1 (2.6%)	3.5±0.5 (0.0%)	1.3±0.7 (2.6%)	32.7±51.8 (25.6%)		25.6%
Other 934 participants	1.2±0.2 (5.0%)	3.5±0.7 (6.9%)	1.2±0.8 (7.7%)	32.9±113.3 (16.8%)		6.9%

Mean + SD (percentage outside the reference range)

Table 8[.] Blood test results

Table 9: Urinary iodine test results

(µg/day)

	Minimum	25 th percentile	Median	75 th percentile	Maximum
Malignant or suspicious 39 participants	35	93	189	415	1,783
Other 923 participants	32	119	192	345	31,920

1) FT4: free thyroxine; thyroid hormone binding 4 iodines; higher among patients with thyrotoxicosis (such as Graves' disease) and lower with hypothyroidism (such as Hashimoto's thyroiditis).

2) FT3: free triiodothyronine; thyroid hormone binding 3 iodine; higher among patients with thyrotoxicosis (such as Graves' disease) and lower with hypothyroidism (such as Hashimoto's thyroiditis).

3) TSH: thyroid-stimulating hormone; higher among patients with Hashimoto's disease and lower with Graves' disease.

4) Tg: thyroglobulin; higher when thyroid tissue is destroyed or when neoplastic tissue produces thyroglobulin.

5) TgAb: anti-thyroglobulin antibody; higher among patients with Hashimoto's disease and Graves' disease.

6) TPOAb: anti-thyroid peroxidase antibody; higher among patients with Hashimoto's disease or Graves' disease.

7) Reference interval varies by age.

2.2-6 Confirmatory examination results by area

The percentage of those with malignant or suspicious nodules was 0.03% in Hamadori, 0.02% in Nakadori and Aizu, and 0.01% in the 13 municipalities of the designated evacuation zone.

	Numbers of participants	Those referred to confirmatory exam	Percentage (%)	Confirmatory exam participants	Malignant or suspicious	Percentage (%)
	а	b	b/a		С	c/a
13 municipalities ¹⁾	22,565	151	0.7	123	2	0.01
Nakadori ^{i 2)}	104,145	712	0.7	517	23	0.02
Hamadori ³⁾	33,765	324	1.0	245	9	0.03
Aizu ⁴⁾	22,935	207	0.9	151	5	0.02
Total	183,410	1,394	0.8	1,036	39	0.02

Table 10 Confirmatory examination results by the area

1) Tamura, Minami-soma, Date, Kawamata, Hirono, Naraha, Tomioka, Kawauchi, Okuma, Futaba, Namie, Katsurao, litate

2) Fukushima, Koriyama, Shirakawa, Sukagawa, Nihonmatsu, Motomiya, Koori, Kunimi, Otama, Kagamiishi, Tenei, Nishigo, Izumizaki, Nakajima, Yabuki, Tanagura, Yamatsuri, Hanawa, Samegawa, Ishikawa, Tamakawa, Hirata, Asakawa, Furudono, Miharu, Ono

3) Iwaki, Soma, Shinchi

4) Aizuwakamatsu, Kitakata, Shimogo, Hinoemata, Tadami, Minamiaizu, Kitashiobara, Nishiaizu, Bandai, Inawashiro, Aizubange, Yugawa, Yanaizu, Mishima, Kaneyama, Showa, Aizumisato

3. Mental Health Care Support

We provide the following support for thyroid examination participants.

3.1 Support for Primary Examination Participants

After the examination, medical doctors explain the results, showing ultrasound images in the private consultation booths set up at examination venues.

Those consultation booths have been set up and utilized at all examination venues since April 2018, and as of June 30, 2,654 participants (100%) of 2,655 have visited for consultation.

3.2 On-location Lectures and Information Sessions

To help participants and/or their parents and guardians deepen understanding of the thyroid examination, we have been conducting on-location lectures and information sessions since April 2018. By March 31, 2020, a total of 1,063 people had participated in these sessions, offered at 32 locations.

3.3 Support for Confirmatory Examination Participants

A support team has been launched at Fukushima Medical University to address anxieties and concerns of confirmatory examination participants. The team also answers any questions and offers on-line counseling as well.

Since the start of the fourth-round survey, 483 participants (163 males and 320 females) have received support as of June 30, 2022. The total number of support sessions provided was 959. Of these, 480 (50.1%) received support at the first examination and 479 (49.9%) at subsequent examinations.

For those who proceed to national health insurance medical care after their examinations, the support team continues to provide support in cooperation with medical staff at participating hospitals.

Implementation status of the TUE primary examination by municipality

As of June 30, 2022

6	Number of eligible persons	Participants	participation	Participation %		icipants and par by age group ²⁾	ticipation rate	Participants reside outside Fukushima	%
	а	b	outside Fukushima ¹⁾	b/a	6-11	12-17	18-24	с	c/b
Municipalities surveye	ed in FY2018	}							
Kauranata	4 0 2 2	4 405	20	<u> </u>	472	576	87	60	<u> </u>
Kawamata	1,832	1,135	26	62.0	41.6	50.7	7.7	68	6.0
Namie	2,858	1,520	311	53.2	587	718	215	383	25.2
Indiffic	2,000	1,520	511	55.2	38.6	47.2	14.1	505	25.2
litate	852	544	19	63.8	220	279	45	40	7.4
		0.1			40.4	51.3	8.3		
Minamisoma	10,201	6,008	845	58.9	2,495	2,980	533	1,000	16.6
					41.5	49.6	8.9		
Date	8,781	5,929	194	67.5	2,333 39.3	3,042 51.3	<u>554</u> 9.3	244	4.1
					1,515	1,640	9.3 270		
Tamura	5,435	3,425	71	63.0	44.2	47.9	7.9	139	4.1
					183	215	50		
Hirono	801	448	35	55.9	40.8	48.0	11.2	45	10.0
	4 00 4	500	50	547	220	296	82		40.5
Naraha	1,094	598	50	54.7	36.8	49.5	13.7	63	10.5
Tomiaka	2 240	1 104	100	F1 O	445	571	178	222	10.4
Tomioka	2,340	1,194	198	51.0	37.3	47.8	14.9	232	19.4
Kawauchi	267	152	10	56.9	55	85	12	14	9.2
Nawauchi	207	152	10	50.9	36.2	55.9	7.9	14	9.2
Okuma	2,020	1,139	211	56.4	442	551	146	238	20.9
onunia	2,020	1,100	2		38.8	48.4	12.8	200	20.0
Futaba	978	364	63	37.2	146	179	39	71	19.5
				-	40.1	49.2	10.7		
Katsurao	174	109	3	62.6	39	57	13	9	8.3
					35.8	52.3	11.9		
Fukushima	43,240	29,067	1,854	67.2	11,774 40.5	14,384 49.5	2,909 10.0	2,053	7.1
					2,275	2,780	420		
Nihonmatsu	8,104	5,475	205	67.6	41.6	50.8	7.7	213	3.9
					1,401	1,564	237		
Motomiya	4,910	3,202	101	65.2	43.8	48.8	7.4	129	4.0
2 1					416	440	62		
Otama	1,285	918	26	71.4	45.3	47.9	6.8	21	2.3
K a ni a su a	50.550	00.000	0.500	00 5	13,495	16,706	3,189	0.740	
Koriyama	52,558	33,390	2,539	63.5	40.4	50.0	9.6	2,748	8.2
Koori	1 600	1 1 2 0	32	70.2	465	545	120	45	4.0
KOOH	1,609	1,130	32	70.2	41.2	48.2	10.6	45	4.0
Kunimi	1,204	810	18	67.3	296	432	82	29	3.6
Kunimi	1,204	810	10	07.5	36.5	53.3	10.1	29	5.0
Tenei	839	525	8	62.6	224	262	39	12	2.3
i enei	039	525	0	02.0	42.7	49.9	7.4	12	2.5
Shirakawa	9,970	6,522	276	65.4	2,624	3,294	604	345	5.3
Crincitawa	5,575	5,022	210	00.4	40.2	50.5	9.3	0+0	0.0
Nishigo	3,263	2,214	96	67.9	920	1,083	211	117	5.3
	·,	, -			41.6	48.9	9.5		
Izumizaki	1,025	668	5	65.2	277	336	55	8	1.2
┟─────┼					41.5	50.3	8.2		
Miharu	2,383	1,516	37	63.6	562 37.1	780 51.5	174 11.5	45	3.0
┢──────┼					43,881	51.5	10,326		
Subtotal	168,023	108,002	7,233	64.3	43,001	49.8	9.6	8,311	7.7

*1) The number of participants who received the examination at facilities outside Fukushima (as of May 31, 2022)

*2) Split cells show the number of participants above the corresponding percentage.

*3) The number of participants who have resident registration outside of Fukushima.

· Age groups are based on participants' age at the Full-Scale Survey (the fourth-round survey). This applies to other tables hereafter.

	Number of eligible persons	Participants	participation	Participation %		icipants and part by age group ²⁾	ticipation rate	Participants reside outside Fukushima	%
	а	b	outside Fukushima ¹⁾	b/a	6-11	12-17	18-24	с	c/b
unicipalities surve	eyed in FY2019	9		-					
Iwaki	49,643	29,893	1,673	60.2	9,471	16,105	4,317	1,918	6.
					31.7 2,764	53.9 3,935	14.4 854		
Sukagawa	12,377	7,553	221	61.0	36.6	52.1	11.3	270	3.
Soma	5,507	3,193	215	58.0	1,263	1,647	283	259	8.
Conta	0,001	0,100	210	00.0	39.6	51.6	8.9	200	
Kagamiishi	2,133	1,323	33	62.0	491 37.1	702 53.1	130 9.8	37	2.
Chinahi	1 1 6 2	670	22	EQ 4	233	375	71	24	F
Shinchi	1,162	679	33	58.4	34.3	55.2	10.5	34	5
Nakajima	849	505	8	59.5	192	265	48	9	1
					38.0 727	52.5 837	9.5 123		
Yabuki	2,671	1,687	28	63.2	43.1	49.6	7.3	42	2.
Ishikawa	2,182	1,349	26	61.8	543	677	129	45	3.
	, -	,			40.3 213	50.2 238	9.6 29		-
Yamatsuri	816	480	15	58.8	44.4	49.6	6.0	19	4.
Asakawa	1,064	661	22	62.1	238	360	63	29	4.
Asakawa	1,004	001	22	02.1	36.0	54.5	9.5	29	4.
Hirata	969	608	8	62.7	245	308	55	8	1.
					40.3 589	50.7 782	9.0 98		
Tanagura	2,399	1,469	32	61.2	40.1	53.2	6.7	40	2.
Hanawa	1,299	707	16	54.4	289	371	47	25	3.
Tanawa	1,200	101	10	54.4	40.9	52.5	6.6	23	5.
Samekawa	519	307	7	59.2	137	156	14	7	2.
					44.6 354	50.8 448	4.6		
Ono	1,487	879	9	59.1	40.3	51.0	8.8	13	1.
Tamakawa	1,052	658	4	62.5	253	357	48	7	1.
Tumanawa	1,002			02.0	38.4	54.3	7.3		
Furudono	817	522	20	63.9	208 39.8	251 48.1	63 12.1	16	3.
	07				16	16	4		0
Hinoemata	87	36	1	41.4	44.4	44.4	11.1	1	2.
Minamiaizu	2,128	1,170	19	55.0	482	605	83	38	3.
					41.2 21	51.7 41	7.1		
Kaneyama	147	72	1	49.0	29.2	56.9	13.9	2	2.
Showa	115	68	3	59.1	31	33	4	3	4.
Ghowa	110	00	Ů	00.1	45.6	48.5	5.9	Ŭ	т.
Mishima	148	84	0	56.8	29 34.5	50 59.5	5 6.0	0	0.
01.1		107			179	222	26		
Shimogo	747	427	5	57.2	41.9	52.0	6.1	14	3.
Kitakata	6,948	4,100	82	59.0	1,489	2,224	387	127	3.
	- ,	,			36.3 169	54.2 190	9.4 49		-
Nishiaizu	761	408	10	53.6	41.4	46.6	12.0	15	3.
Tadami	555	335	6	60.4	138	170	27	8	2.
Tauanni	555	335	0	00.4	41.2	50.7	8.1	0	Ζ.
Inawashiro	2,069	1,204	28	58.2	507 42.1	593 49.3	104 8.6	38	3.
D					109	49.3	23		-
Bandai	477	289	8	60.6	37.7	54.3	8.0	9	3.
Kitashiobara	445	280	3	62.9	115	145	20	6	2.
					41.1 634	51.8 896	7.1 195		
Aizumisato	2,823	1,725	33	61.1	36.8	51.9	195	52	3.
Aizubange	2,402	1,422	39	59.2	540	724	158	48	3.
лицинуе	2,402	1,422	39		38.0	50.9	11.1	40	3.
Yanaizu	464	284	2	61.2	115	143	26	5	1.
					40.5 3,889	50.4 5,589	9.2 1,202		
Aizuwakamatsu	18,424	10,680	385	58.0	3,889	52.3	11.3	505	4
Yugawa	519	351	6	67.6	123	178	50	13	3
i uyawa	519	301	0	07.0	35.0	50.7	14.2	13	3.
Subtotal	126,205	75,408	3,001	59.8	26,796 35.5	39,790	8,822	3,662	4.
			l		33.3	52.8	11.7		
	294,228	183,410	10,234	62.3	70,677	93,585	19,148		6.

Implementation status of the TUE examination conducted outside Fukushima, by prefecture

As of May 31	1, 2022
--------------	---------

Prefecture	Number of medical facilities	Participants	Prefecture	Number of medical facilities	Participants	Prefecture	Number of medical facilities	Participants
Hokkaido	7	279	Fukui	1	18	Hiroshima	2	27
Aomori	2	124	Yamanashi	2	87	Yamaguchi	1	21
lwate	3	250	Nagano	3	123	Tokushima	1	5
Miyagi	2	2,256	Gifu	1	29	Kagawa	1	25
Akita	1	156	Shizuoka	3	83	Ehime	1	15
Yamagata	3	472	Aichi	5	179	Kochi	1	11
Ibaraki	4	571	Mie	1	17	Fukuoka	3	73
Tochigi	8	632	shiga	1	14	Saga	1	1
Gunma	2	174	Kyoto	3	80	Nagasaki	3	25
Saitama	4	530	Osaka	8	174	Kumamoto	1	28
Chiba	5	471	Hyogo	2	124	Oita	1	13
Tokyo	19	1,727	Nara	2	24	Miyazaki	1	20
Kanagawa	7	753	Wakayama	1	9	Kagoshima	1	5
Niigata	3	448	Tottori	1	7	Okinawa	1	34
Toyama	2	27	Shimane	1	11			
lshikawa	1	35	Okayama	3	47	Total	130	10,234

The number of participants who received examinations at medical facilities outside Fukushima.

Appendix 3 TUE primary examination results by municipality

As of June 30, 2022

	Number of	Those with finalized results b	Ν	lumber of partic		e	Number of pain		Number of partic	pants with cy
	participants		A		,		9	6	9	6
-	а	% b/a	A1	A2	В	С	≥5.1mm	\leq 5.0mm	≥20.1mm	≤ 20.0mm
lunicipalities surve	eyed in FY2				_					
Kawamata	1,135	1,135	408	722	5	0	4	3	1	7.
		100.0	35.9	63.6	0.4	0.0	0.4	0.3	0.1	64
Namie	1,520	1,520	499	1,007	14	0	14	6	0	1,0
		100.0	32.8	66.3	0.9	0.0	0.9	0.4	0.0	6
litate	544	544	203	337	4	0	4	2	0	3
		100.0	37.3	61.9	0.7	0.0	0.7	0.4	0.0	6
Minamisoma	6,008	6,008	2,117	3,847	44	0	44	29	0	3,8
		100.0	35.2	64.0	0.7	0.0	0.7	0.5	0.0	6
Date	5,929	5,929	2,043	3,851	35	0	35	19	0	3,8
	,	100.0	34.5	65.0	0.6	0.0	0.6	0.3	0.0	6
Tamura	3,425	3,425	1,271	2,132	22	0	22	10	0	2,1
		100.0	37.1	62.2	0.6	0.0	0.6	0.3	0.0	6
Hirono	448	448	169	273	6	0	6	3	0	2
		100.0	37.7	60.9	1.3	0.0	1.3	0.7	0.0	6
Naraha	598	598	208	388	2	0	2	1	0	;
Harana	000	100.0	34.8	64.9	0.3	0.0	0.3	0.2	0.0	6
Tomioka	1,194	1,194	423	764	7	0	7	4	0	-
Tornioka	1,134	100.0	35.4	64.0	0.6	0.0	0.6	0.3	0.0	6
Kawauchi	152	152	45	105	2	0	2	0	0	
Nawauchi	152	100.0	29.6	69.1	1.3	0.0	1.3	0.0	0.0	7
Okuma	1,139	1,139	392	739	8	0	8	5	0	
Okuma	1,139	100.0	34.4	64.9	0.7	0.0	0.7	0.4	0.0	6
E. take	204	364	110	253	1	0	1	0	0	
Futaba	364	100.0	30.2	69.5	0.3	0.0	0.3	0.0	0.0	6
Kataraa	100	109	34	74	1	0	1	0	0	
Katsurao	109	100.0	31.2	67.9	0.9	0.0	0.9	0.0	0.0	e
Euloushime	20.007	29,067	10,021	18,871	175	0	174	94	1	18,
Fukushima	29,067	100.0	34.5	64.9	0.6	0.0	0.6	0.3	0.0	6
		5,475	1,912	3,510	53	0	52	20	1	3,
Nihonmatsu	5,475	100.0	34.9	64.1	1.0	0.0	0.9	0.4	0.0	6
		3,202	1,124	2,064	14	0	14	8	0	2,
Motomiya	3,202	100.0	35.1	64.5	0.4	0.0	0.4	0.2	0.0	e
		918	305	606	7	0	7	2	0	
Otama	918	100.0	33.2	66.0	0.8	0.0	0.8	0.2	0.0	e
		33,390	10,985	22,189	216	0	215	116	1	22,
Koriyama	33,390	100.0	32.9	66.5	0.6	0.0	0.6	0.3	0.0	, 6
		1,130	400	723	7	0	7	2		
Koori	1,130	100.0	35.4	64.0	0.6	0.0	0.6	0.2	0.0	6
		810	261	540	9	0	9	1	0	
Kunimi	810	100.0	32.2	66.7	1.1	0.0	1.1	0.1	0.0	e
		525	192	329	4	0.0	4	2	0	
Tenei	525	100.0	36.6	62.7	0.8	0.0	0.8	0.4	0.0	e
		6,522	2,277	4,203	42	0.0	42	26	0.0	4,
Shirakawa	6,522	100.0	34.9	64.4	0.6	0.0	0.6	0.4	0.0	-,
		2,214	740	1,460	14	0.0	14	9	0.0	1,4
Nishigo	2,214	100.0		65.9	0.6	0.0	0.6		0.0	6
			33.4					0.4		
Izumizaki	668	668	243	423	2	0	2	2	0	
		100.0	36.4	63.3	0.3	0.0	0.3	0.3	0.0	6
Miharu	1,516	1,516	513	991	12	0	12	5	0	
		100.0	33.8	65.4	0.8	0.0	0.8	0.3	0.0	6
Subtotal	108,002	108,002	36,895	70,401	706	0	702	369	4	70,
	•	100.0	34.2	65.2	0.7	0.0	0.6	0.3	0.0	6

		Those with finalized results	١	lumber of partic	cipants by grad	le		rticipants with	Number of participants with cysts		
	Number of participants	b		9	6		nod	ules	,		
+	participarits	%	A1				a	%	Q	%	
		b/a	A1	A2	В	С	≥5.1mm	≤ 5.0mm	≥20.1mm	≤ 20.0mm	
	а	D/a	AI	AZ			25.111111	≥ 5.0mm	220.111111	≤ 20.00000	

Municipalities surveyed in FY2019


lwaki	29,893 —	29,893	9,435	20,179	279	0	278	118	1	20,3
		100.0	31.6	67.5	0.9 70	0.0	0.9	0.4 45	0.0	67
Sukagawa	7,553	7,553 100.0	2,376 31.5	5,107 67.6	0.9	0.0	70 0.9	45 0.6	0.0	5,1
		3,193	1,058	2,095	40	0.0	40	11	0.0	2,1
Soma	3,193 —	100.0	33.1	65.6	1.3	0.0	1.3	0.3	0.0	66
Kagamiishi	1,323 -	1,323	410	900	13	0	13	6	0	9
	1,020	100.0	31.0	68.0	1.0	0.0	1.0	0.5	0.0	6
Shinchi	679 —	679	229	445	5	0	5	3	0	4
		100.0 505	33.7 175	65.5 327	0.7	0.0	0.7	0.4	0.0	6
Nakajima	505	100.0	34.7	64.8	0.6	0.0	0.6	0.2	0.0	6
Mahada	4 007	1,687	613	1,066	8	0	8	7	0	1,0
Yabuki	1,687	100.0	36.3	63.2	0.5	0.0	0.5	0.4	0.0	6
lshikawa	1,349 —	1,349	460	875	14	0	14	4	0	8
	.,	100.0	34.1	64.9	1.0	0.0	1.0	0.3	0.0	6
Yamatsuri	480 -	480	151	329	0	0	0	2	0	:
		100.0 661	31.5 211	68.5 443	0.0	0.0	0.0	0.4	0.0 0	6
Asakawa	661	100.0	31.9	67.0	1.1	0.0	1.1	0.5	0.0	6
		608	235	371	2	0.0	2	2	0.0	;
Hirata	608	100.0	38.7	61.0	0.3	0.0	0.3	0.3	0.0	6
Topoguro	1,469	1,469	541	918	10	0	10	7	0	9
Tanagura	1,409	100.0	36.8	62.5	0.7	0.0	0.7	0.5	0.0	6
Hanawa	707	707	267	435	5	0	5	2	0	4
		100.0	37.8	61.5	0.7	0.0	0.7	0.3	0.0	6
Samegawa	307	307	130	174	3	0	3	0	0	
		100.0 879	42.3 273	56.7 597	1.0 9	0.0	1.0 9	0.0	0.0	5
Ono	879 -	100.0	31.1	67.9	9 1.0	0.0	1.0	0.1	0.0	6
_		658	243	404	11	0.0	11	2	0.0	
Tamagawa	658 —	100.0	36.9	61.4	1.7	0.0	1.7	0.3	0.0	6
Furudono	522	522	202	318	2	0	2	2	0	
1 diddono	522	100.0	38.7	60.9	0.4	0.0	0.4	0.4	0.0	6
Hinoemata	36 —	36	12	24	0	0	0	0	0	
		100.0	33.3	66.7	0.0	0.0	0.0	0.0	0.0	6
Minamiaizu	1,170	1,170 100.0	436 37.3	722 61.7	12 1.0	0.0	12 1.0	3 0.3	0.0	6
		72	22	49	1.0	0.0	1.0	0.5	0.0	
Kaneyama	72 —	100.0	30.6	68.1	1.4	0.0	1.4	0.0	0.0	6
Showa	68 -	68	23	45	0	0	0	0	0	
Showa	00	100.0	33.8	66.2	0.0	0.0	0.0	0.0	0.0	6
Mishima	84	84	21	62	1	0	1	0	0	
		100.0	25.0	73.8	1.2	0.0	1.2	0.0	0.0	7
Shimogo	427	427 100.0	162 37.9	261 61.1	4	0.0	4	0.0	0.0	6
		4,100	1,409	2,659	32	0.0	32	22	0.0	2,
Kitakata	4,100	100.0	34.4	64.9	0.8	0.0	0.8	0.5	0.0	,
Nishisim	400	408	149	256	3	0	3	1	0	
Nishiaizu	408	100.0	36.5	62.7	0.7	0.0	0.7	0.2	0.0	6
Tadami	335 -	335	117	217	1	0	1	0	0	
		100.0	34.9	64.8	0.3	0.0	0.3	0.0	0.0	6
Inawashiro	1,204 —	1,204	418	770	16	0	16	4	0	
		100.0 289	34.7 83	64.0 202	1.3 4	0.0	1.3 4	0.3	0.0	6
Bandai	289	100.0	28.7	69.9	4	0.0	4	0.3	0.0	7
Kite e kiek soo	000	280	96	182	2	0	2	0	0.0	
Kitashiobara	280	100.0	34.3	65.0	0.7	0.0	0.7	0.0	0.0	(
Aizumisato	1,725 -	1,725	553	1,156	16	0	16	8	0	1,
71201115010	1,720	100.0	32.1	67.0	0.9	0.0	0.9	0.5	0.0	(
Aizubange	1,422 -	1,422	446	965	11	0	11	6	0	
		100.0	31.4	67.9 181	0.8	0.0	0.8	0.4	0.0	(
Yanaizu	284 —	284 100.0	103 36.3	181 63.7	0.0	0.0	0.0	0.0	0 0.0	
<u> </u>		10,680	3,616	6,964	100	0.0	100	36	0.0	7,
Aizuwakamatu	10,680	100.0	33.9	65.2	0.9	0.0	0.9	0.3	0.0	
Vugeure	254	351	142	205	4	0	4	3	0	
Yugawa	351 —	100.0	40.5	58.4	1.1	0.0	1.1	0.9	0.0	;
Subtotal	75,408 -	75,408	24,817	49,903	688	0	687	300	1	50,
	. 0, 100	100.0	32.9	66.2	0.9	0.0	0.9	0.4	0.0	6
I		183,410	61,712	120,304	1,394	0	1,389	669	5	121,
Total	183,410 -	,	2.,. 14	,	.,00-	0	.,000	000	5	,

Appendix 4 1 TUE primary examination results by age and gender


As of June 30, 2022

(Person)

Grade			1	4				в			С			合計		
		A1 A2				B			J			ып				
Age group	Male	Femal	Total	Male	Femal	Total	Male	Femal	Total	Male	Femal	Total	Male	Femal	Total	
6-11	13,179	11,563	24,742	23,008	22,831	45,839	39	57	96	0	0	0	36,226	34,451	70,677	
12-17	16,059	13,652	29,711	31,182	31,853	63,035	284	555	839	0	0	0	47,525	46,060	93,585	
18-24	3,430	3,829	7,259	5,294	6,136	11,430	136	323	459	0	0	0	8,860	10,288	19,148	
Total	32,668	29,044	61,712	59,484	60,820	120,304	459	935	1,394	0	0	0	92,611	90,799	183,410	




Results by age group (Female)



2 Nodule characteristics

As of June 30, 2022 (Persons)


Nodule size	Total			Grad		
inodule size	Total	Male	Female	Grad	le	
None	181,352	91,915	89,437	A1	98.9%	
≤3.00mm	65	31	34	A2	0.4%	
3.1 - 5.0mm	604	207	397		0.470	
5.1 - 10.0mm	925	313	612			
10.1 - 15.0mm	282	94	188			
15.1 - 20.0mm	94	27	67	В	0.8%	
20.1 - 25.0mm	43	13	30			
≥25.1mm	45	11	34			
Total	183,410	92,611	90,799			



No nodules

■Nodules ≤5.0mm


■Nodules ≥5.1mm




As of June 30, 2022

(Persons)

					(Persons)	
Cyst size	Total			Grad	۵	
0931 3120	Total	Male	Female	Oldo		
None	62,401	32,920	29,481	A1	74.6%	
≤3.0mm	74,403	39,065	35,338		74.070	
3.1 - 5.0mm	41,139	18,684	22,455			
5.1 - 10.0mm	5,362	1,907	3,455	6 A2	25.4%	
10.1 - 15.0mm	91	33	58		25.4%	
15.1 - 20.0mm	9	1	8			
20.1 - 25.0mm	4	0	4	В	0.003%	
≥25.1mm	1	1	0	D	0.003%	
計	183,410	92,611	90,799			





Implementation status of the TUE confirmatory examination by area

As of June 30, 2022

			Confi	rmatory exa	m participan	ts		Those w	ith finalised	results	
	Primary examination participants	xamination confirmatory		Age 6-11	Age 12-17	Age ≥18	Total	A1	A2	Not A1 or A2	FNAC
	а	b	с	d	е	f	g	h	i	j	k
		b/a	c/b	d/c	e/c	f/c	g/c	h/g	i/g	j/g	k/i
12 municipalities 1	22,565	151	123	7	71	45	1	9 1	8	110	7
13 municipalities ¹	22,505	0.7	81.5	5.7	57.7	36.6	96	.7 0.8	6.7	92.4	6.4
Nakadori ²⁾	104,145	712	517	45	279	193	5)8 3	52	453	49
Nakadon /	104,145	0.7	72.6	8.7	54.0	37.3	98	.3 0.6	10.2	89.2	10.8
Hamadori ³⁾	33,765	324	245	10	143	92	24	13 1	17	225	23
Hamadon	33,705	1.0	75.6	4.1	58.4	37.6	99	.2 0.4	7.0	92.6	10.2
Aizu ⁴⁾	22,935	207	151	7	82	62	14	16 1	11	134	12
AIZU /	22,935	0.9	72.9	4.6	54.3	41.1	96	.7 0.7	7.5	91.8	9.0
合計	183,410	1,394	1,036	69	575	392	1,0	6 6	88	922	91
	103,410	0.8	74.3	6.7	55.5	37.8	98	.1 0.6	8.7	90.7	9.9

1) Tamura, Minami-soma, Date, Kawamata, Hirono, Naraha, Tomioka, Kawauchi, Okuma, Futaba, Namie, Katsurao, litate

Fukushima, Koriyama, Shirakawa, Sukagawa, Nihonmatsu, Motomiya, Koori, Kunimi, Otama, 2) Kagamiishi, Tenei, Nishigo, Izumizaki, Nakajima, Yabuki, Tanagura, Yamatsuri, Hanawa, Samegawa, Ishikawa, Tamakawa, Hirata, Asakawa, Furudono, Miharu, Ono

3) 4) Iwaki, Soma, Shinchi

Aizuwakamatsu, Kitakata, Shimogo, Hinoemata, Tadami, Minamiaizu, Kitashiobara, Nishiaizu, Bandai, Inawashiro, Aizubange, Yugawa, Yanaizu, Mishima, Kaneyama, Showa, Aizumisato

Appendix 6

Surgical cases for malignancy or suspicion of malignancy

1. Municipalities surveyed in FY2018 Malignant or suspicious for malignancy:	22 (18 surgical cases: 18 papillary thyroid carcinomas)
2. Municipalities surveyed in FY2019 Malignant or suspicious for malignancy:	17 (16 surgical case: 16 papillary thyroid carcinomas)
3. Total Malignant or suspicious for malignancy:	39 (34 surgical cases: 34 papillary thyroid carcinomas)

Report on the Thyroid Ultrasound Examination (TUE) Full-Scale Survey (the fifth-round survey)

As of June 30, 2022

1. Summary

1.1 Purpose

In order to monitor the long-term health of children, we continued the Full-Scale Survey (now fifthround survey), following the Preliminary Baseline Survey for initial assessment of thyroid glands, and three Full-Scale Surveys (second-, third-, and fourth-round surveys) to continuously monitor the status of thyroid glands.

1.2 Eligible Persons

All Fukushima residents 18 years old or younger at the time of earthquake (those born between April 2, 1992 and April 1, 2012).

1.3 Implementation Period

From FY2020 to FY2022, starting in April 2020.

1.3-1 For those 18 years old or younger The examination implementation period covers 3 years, from FY2020 through FY2022.

1.3-2 For those 19 years old or older

The examination is carried out on an age group basis (i.e., school grade). FY2020: those born in FY1998 and FY2000 FY2021: those born in FY1999 and FY2001 FY2022: N/A

1.3-3 For those 25 years old or older
Those who are older than 20 are recommended to receive the examination every 5 years.
FY2020: those born in FY1995
FY2021: those born in FY1996
FY2022: those born in FY1997
Results of the survey for those 25 years old will be reported separately.

1.4 Implementing Organizations (Number of medical facilities and institutions with agreements for conducting thyroid examinations)

Fukushima Prefecture commissioned Fukushima Medical University (FMU) to conduct the survey in cooperation with organizations inside and outside Fukushima for the convenience of participants (the number of medical facilities shown below is as of June 30, 2022).

1.4-1 Primary examination facilitiesInside Fukushima Prefecture85Outside Fukushima Prefecture130

1.4-2 Confirmatory examination facilitiesInside Fukushima Prefecture5 including FMUOutside Fukushima Prefecture37

1.5 Methods

1.5-1 Primary examination

Ultrasonography of the thyroid gland. Multiple specialists assess examination results based on the following criteria:

- Grade A

A1: No nodules/cysts A2: Nodules ≤ 5.0 mm or cysts ≤ 20.0 mm

- Grade B

B: Nodules \geq 5.1 mm or cysts \geq 20.1 mm Includes A2 results that need to be re-classified as Grade B for confirmatory examination.


-Grade C

C: Prompt confirmatory examination warranted, based on clinical judgment of initial results.

1.5-2 Confirmatory examination

For those with B or C test results, this secondary examination includes ultrasonography of the thyroid gland, blood and urine tests, and Fine Needle Aspiration Cytology (FNAC, if necessary) Priority is given to those in urgent clinical need. A medical follow-up may be recommended based on confirmatory exam results.

1.5-3 Flow chart





1.6 Municipalities by examination fiscal year

The municipalities by examination (for those 18 years old or younger) were carried out in FY2020 to FY2022 are as follows:




Figure. 2 Municipalities covered for primary examinations at elementary and junior high schools




Figure. 3 Municipalities covered for primary examinations at high schools and other facilities

2. Overview of the Survey (as of June 30, 2022)

2.1 Results of the Primary Examination

2.1-1 Implementation status

The primary examination was carried out for 80,205 participants (31.7%) by June 30, 2022. (Please refer to Appendix 1 and 2 for the primary survey implementation status by municipalities and venues outside Fukushima.)

Results for 75,868 participants (94.6%) have been finalized and individual result reports were sent out. (Refer to Appendix 3 for Result by municipalities)

Of these, 22,151 (29.2%) had Grade A1 results, 52,778 (69.6%) had Grade A2, 939 (1.2%) had Grade B, and none had Grade C.

Table 1 Progress and results of the primary examination

		Pa	rticipants	s(%)	Participants with finalized results(%)									
	Eligible			Other					A		Those r	eferred	to Confi	rmatory
				prefectu			A	1	A	2	В		(0
	а	b	(b/a)	re	С	(c/b)	d	(d/c)	е	(e/c)	f	(f/c)	g	(g/c)
FY2020	144,905	65,617	(45.3)	5,272	65,335	(99.6)	18,890	(28.9)	45,752	(70.0)	693	1.1	0	(0.0)
FY2021	108,003	14,588	(13.5)	2,325	10,533	(72.2)	3,261	(31.0)	7,026	(66.7)	246	2.3	0	(0.0)
Total	252,908	80,205	(31.7)	7,597	75,868	(94.6)	22,151	(29.2)	52,778	(69.6)	939	1.2	0	(0.0)

Table 2 Number and percentage of participants with nodules/cysts (see details for Appendix 4)

Respective	Participants with finalized		Ν	lodules		Cysts					
fiscal year	results	≧5.1mm		≦5.0mm		≥20	0.1mm	≤20.0mm			
	а	b	(b/a)	С	(c/a)	d	(d/a)	е	(e/a)		
FY2020	65,335	693	(1.1)	357	(0.5)		1 (0.0)	46,142	(70.6)		
FY2021	10,533	246	(2.3)	104	(1.0)		0 (0.0)	7,159	(68.0)		
Total	75,868	939	(1.2)	461	(0.6)		1 (0.0)	53,301	(70.3)		

Proportions are rounded to a lower decimal place. This applies to other tables as well.

Those who receive the examination at 5-year intervals (born between FY1992 and FY1997) are excluded; their results will be reported separately (i.e., Examination for Age 25)

Examination schedule - respective year of birth and examination fiscal year is as follows:

FY1992 birth year (approx. 23,000) - Examination in FY2017

FY1993 birth year (approx. 22,000) - Examination in FY2018

FY1994 birth year (approx. 22,000) – Examination in FY2019 FY1995 birth year (approx. 21,000) – Examination in FY2020

FY1996 birth year (approx. 21,000) - Examination in FY2021

FY1997 birth year (approx. 20,000) - Examination in FY2022

2.1-2 Participation rate by age group

Table 3 shows the participation rate for the age groups as of April 1 each year.

Table 3 Participation rate by age groups

			Total	8 - 11	12-17	18-24
FY2020	Eligible participants	а	144,905	37,105	61,913	45,887
112020	Examinees	b	65,617	26,398	34,312	4,907
	Examination rate	b/a	45.3	71.1	55.4	10.7
				9 - 11	12-17	18-24
FY2021	Eligible participants	а	108,003	19,739	45,059	43,205
F12021	Examinees	b	14,588	3,561	6,480	4,547
	Examination rate	b/a	13.5	18.0	14.4	10.5
	Eligible participants	а	252,908	56,844	106,972	89,092
Total	Examinees	b	80,205	29,959	40,792	9,454
E	Examination rate	b/a	31.7	52.7	38.1	10.6

2.1-3 Comparison of the fourth- and the fifth-round survey results

Table 4 shows the comparison of two Full-Scale Surveys (fourth- and fifth-round surveys). Among 70,425 participants with Grade A1 or A2 results in the fourth-round survey, 69,918 (99.3%) had Grade A1 or A2 results and 507 (0.7%) had Grade B results in the fifth-round survey. Among 389 participants with Grade B results in the fourth-round survey, 70 (18.0%) had Grade A1 or A2 results and 319 (82.0%) had Grade B results in the fifth-round survey.

Table 4 Comparison of the fourth- and fifth-round surveys (abbreviated 4th and 5th)

			Results of the	Resu	ilts of the 5t	h round sur	vey**
			4th round	A	۱.	В	С
			survey*	A1	A2	D	C
			а	b	С	d	е
			%	b/a	c/a	d/a	e/a
		A1	23,278	16,257	6,931	90	0
	А		(100.0)	(69.8)	(29.8)	(0.4)	(0.0)
	A2		47,147	4,148	42,582	417	0
Results of	f A		(100.0)	(8.8)	(90.3)	(0.9)	(0.0)
the 4th	E	2	389	6	64	319	0
round	L	2	(100.0)	(1.5)	(16.5)	(82.0)	(0.0)
survey	(`	0	0	0	0	0
	С		(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
	No medical		5,054	1,740	3,201	113	0
	examination		(100.0)	(34.4)	(63.3)	(2.2)	(0.0)
Тс	tal		75,868	22,151	52,778	939	0
	Total		(100.0)	(29.2)	(69.6)	(1.2)	(0.0)

*Results of the fourth-round survey are from fifth-round survey participants with finalized results, rather than a breakdown of all fourth-round survey participants.

**Results of the fifth-round survey participants who were diagnosed with each grade in the fourth-round survey.

2.2 Results of the Confirmatory Examination

2.2-1 Implementation status

By June 30, 2022, 583 (62.1%) of 939 eligible persons had participated in the confirmatory examination, and 531 (91.1%) of them had completed the entire examination procedure.

Of the aforementioned 531 participants, 53 (A1: 4, A2: 49) (10.0%) were confirmed to meet A1 or A2 diagnostic criteria by the primary examination standards (including those with other thyroid conditions) after detailed examination; 478 (90.0%) were confirmed to be outside of A1/A2 criteria

	Those referred to confirmatory		Participants (Persons) (%)		al				Those wit	ch finalize	ed results	(Person)		
	exams (Persons)	(Person			(Persons) (%)				A1		A	2		Not A1
	а	b	b/a	с	c/b	d		d/c	е	e/c	f	f/c	g	g/f
FY2020	693	444	(64.1)	405	(91.2)		4	(1.0)	42	(10.4)	359	(88.6)	40	(11.1)
FY2021	246	139	(56.5)	126	(90.6)		0	(0.0)	7	(5.6)	119	(94.4)	8	(6.7)
Total	939	583	(62.1)	531	(91.1)		4	(0.8)	49	(9.2)	478	(90.0)	48	(10.0)

Table 5 Progress and results of the confirmatory examination

2.2-2 Results of Fine Needle Aspiration Cytology (FNAC)

Among those who underwent FNAC, 23 participants had nodules classified as malignant or suspicious for malignancy, of whom 5 were male and 18 were female. The mean age for those participants was 17.2 ± 2.8 years old, and age distribution was from 13 to 23 years old. The mean tumor size was 12.8 ± 8.0 mm (range 7.0 - 46.7 mm)


Fourth-round survey results for the aforementioned 23 participants were: Grade A, 18 persons (A1:7, A2:11); Grade B, 3 persons; not examined, 2 persons.


Table 6 Results of FNAC

A. Municipalities surveyed in FY2020 · Malignant or suspicious for malignancy: · Male to female ratio:	18* 3:15
·Mean age (min-max):	16.8 ± 3.0 years old (13-23)
·Mean size of the tumor:	6.1 ± 3.1 (2-12) at the time of the Earthquake 10.7 \pm 2.7 mm (7.0-16.2 mm)
B. Municipalities surveyed in FY2021	
·Malignant or suspicious for malignancy:	5*
·Male to female ratio:	2:3
·Mean age (min-max):	18.6 \pm 1.1 years old (17-20)
	8.2 \pm 1.8 (6-10) at the time of the Earthquake
•Mean size of the tumor:	20.4±15.1mm (8.9-46.7mm)
C. Total	
• Malignant or suspicious for malignancy:	23*
• Male to female ratio:	5:18
· Mean age (min-max):	17.2 ± 2.8 years old (13-23)
	6.6 ± 3.0 (2-12) at the time of the Earthquake
•Mean size of the tumor:	12.8 ± 8.0 mm (7.0-46.7 mm)

* Appendix 5 shows surgery cases.


2.2-3 Age distribution of malignant or suspicious-for-malignancy cases diagnosed by FNAC Figure 4 shows the age distributions of 23 people with malignant or suspicious nodules based on their age as of March 11, 2011, and Figure 5 shows the age distribution based on their age at the time of confirmatory examination.





Note: Those between 13 to 18 years old at the time of disaster are not included in the fifth-round survey. The horizontal axis begins at -1 to include Fukushima Prefecture residents born between April 2, 2011 and April 1, 2012.

Those born between March 12 and April 1, 2011 are included in age 0.



2.2-4 Basic Survey results of those with malignant or suspicious nodules by FNAC

Of those 23 people with malignant or suspicious nodules, 13 people (56.5%) had participated in the Basic Survey (for external radiation dose estimation), and all 13 received their results. The highest effective dose documented was 2.1 mSv.

Effective			Age at th	ne time of	the disa	ster (as c	of March 1	1, 2011)			
dose (mSv)	0-5		6-10		11	-15	16	-18	Total		
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	
<1.0	0	2	2	3	0	2	0	0	2	7	
1.0-1.9	1	1	0	1	0	0	0	0	1	2	
2.0-4.9	0	1	0	0	0	0	0	0	0	1	
5.0-9.9	0	0	0	0	0	0	0	0	0	0	
10.0-19.9	0	0	0	0	0	0	0	0	0	0	
≥20.0	0	0	0	0	0	0	0	0	0	0	
Total	1	4	2	4	0	2	0	0	3	10	

 Table 7 The details dose estimates for Basic Survey participants (persons)




Figure 6 Effective doses of Basic Survey participants

2.2-5 Blood and urinary iodine test results

FT3²⁾ FT4¹⁾ TSH³⁾ Tg⁴⁾ TqAb⁵⁾ TPOAb⁶⁾ (ng/dL) (pg/mL) $(\mu IU/mL)$ (ng/mL) (IU/mL) (IU/mL) **Reference Range** 0.95-1.74 7) 2.13-4.07 7) 0.34-3.887) ≤33.7 < 28.0 < 16.0 1.2±0.2 3.4±0.4 1.2±0.6 112.8±440.3 Malignant or suspicious: 8.7% 17.4% 23 persons (8.7%) (4.3%) (8.7%) (21.7%)1.2±0.2 3.5±0.5 33.2±97.6 1.3±1.4 Other 470 persons 8.3% 7.4% (5.1%) (5.5%) (8.7%) (16.4%)

Table 8 Blood test results

Mean ± SD (percentage of values outside reference range)

Table 9 Urinary iodine test results

(µg/day)

	Minimum	25th percentile	Median	75th percentile	Maximum
Malignant or suspicious: 23 persons	36	116	219	571	1,311
Other 471 persons	24	111	289	326	12,670

1) FT4: free thyroxine; thyroid hormone binding 4 iodines; higher among patients with thyrotoxicosis (such as Graves' disease) and lower with hypothyroidism (such as Hashimoto's thyroiditis).

2) FT3: free triiodothyronine; thyroid hormone binding 3 iodines; higher among patients with thyrotoxicosis (such as Graves' disease) and lower with hypothyroidism (such as Hashimoto's thyroiditis).

3) TSH: thyroid-stimulating hormone; higher among patients with Hashimoto's disease and lower with Graves' disease.

4) Tg: thyroglobulin; higher when thyroid tissue is destroyed or when neoplastic tissue produces thyroglobulin.

5) TgAb: anti-thyroglobulin antibody; higher among patients with Hashimoto's disease and Graves' disease.

- 6) TPOAb: anti-thyroid peroxidase antibody; higher among patients with Hashimoto's disease or Graves' disease.
- 7) Reference interval varies according to age.

3. Mental Health Care

We provide the following support for thyroid examination participants.

3.1 Support for Primary Examination Participants

After the examination, medical doctors offer person-to-person explanation on examination results, showing ultrasound images in private consultation booths at examination venues set up in public facilities.

Consultation booths were set up at all venues for examinations conducted in and after April 2020, and as of June 30, 2022, all 2,195 participants (100%) have visited these consultation booths.

3.2 On-location Lectures and Information Sessions

To help participants and their parents/guardians improve their understanding of the thyroid examination, we have conducted on-location lectures and information sessions since April 2020.

By June 30, 2022, a total of 481 people participated in these sessions offered at 9 locations. Since the start of these sessions, 15,567 people have participated.

3.3 Support for Confirmatory Examination Participants

A support team has been set up within Fukushima Medical University to offer psychological support to address the anxieties and concerns of confirmatory examination participants during examination. The team also answers questions and offers counseling via our website.

Since the start of the fifth-round survey, 297 participants (97 males and 200 females) have received support as of June 30, 2022. The number of support sessions provided was 518 in total. Of these, 295 (56.9%) received support at the participants' first examination and 223 (43.1%) at subsequent examinations.

For those who proceed to regular insured medical care, the support team continues to provide support in cooperation with teams of medical staff at hospitals.

Implementation status of the TUE primary examination by municipality

As of June 30, 2022

	Number of eligible persons	Participants	Participation	Participation %	Number of parti	cipants and par by age group ²⁾	ticipation rate	Participants reside outside Fukushima	%
	а	b	outside Fukushima ¹⁾	b/a	8-11	12-17	18-24	c ³⁾	c/b
lunicipalities surveye	d in FY2020	1						L1	
Kouranta	4 507	705	10	46.0%	236	429	70	10	2.6
Kawamata	1,567	735	12	46.9%	32.1	58.4	9.5	19	2.6
N	0.470	700	005	00.4%	179	389	160	000	04.0
Namie	2,478	728	225	29.4%	24.6	53.4	22.0	226	31.0
litete	731	202	10	44.00/	84	188	51	10	F
litate	731	323	16	44.2%	26.0	58.2	15.8	19	5.9
Minamisoma	0.054	2 5 5 7	550	40.2%	1,123	1,971	463	554	15.
Winamisoma	8,851	3,557	550	40.2%	31.6	55.4	13.0	554	15.
Date	7,412	4,010	158	54.1%	1,140	2,266	604	141	3.
Dale	7,412	4,010	156	54.1%	28.4	56.5	15.1	141	5.
Tamura	4,577	2,226	51	48.6%	794	1,199	233	59	2.
Tamura	4,577	2,220	51	40.076	35.7	53.9	10.5	59	Ζ.
Hirono	647	195	28	30.1%	55	104	36	25	12.
TIIIOIIO	047	190	20	50.170	28.2	53.3	18.5	25	12.
Naraha	916	177	39	19.3%	45	79	53	36	20.
Indialia	310	111		19.570	25.4	44.6	29.9	50	20.
Tomioka	1,980	420	115	21.2%	105	201	114	116	27.
топнока	1,900	420	115	21.270	25.0	47.9	27.1	110	21.
Kawauchi	225	84	7	37.3%	18	52	14	5	6.
Rawauchi	225	04	1	57.576	21.4	61.9	16.7	5	0
Okuma	1,771	391	114	22.1%	105	178	108	109	27
Okuma	1,771	591	114	22.170	26.9	45.5	27.6	109	21.
Futaba	839	160	45	19.1%	41	89	30	46	28.
Fulaba	039	100	43	19.170	25.6	55.6	18.8	40	20.
Katsurao	148	57	3	38.5%	13	32	12	3	5.
Raisarao	140	57	Ŭ	00.070	22.8	56.1	21.1	9	0.
Fukushima	37,320	18,260	1,358	48.9%	4,817	10,838	2,605	1,269	6
i ukushimu	07,020	10,200	1,000	40.570	26.4	59.4	14.3	1,200	0
Nihonmatsu	6,920	3,672	155	53.1%	1,117	2,138	417	136	3
, moninatou	0,020	0,012			30.4	58.2	11.4		
Motomiya	4,232	2,181	77	51.5%	657	1,286	238	70	3
Motorniya	1,202	2,101		01.070	30.1	59.0	10.9	10	0
Otama	1,122	676	18	60.2%	213	381	82	12	1.
Otama	1,122	0/0	10	00.270	31.5	56.4	12.1	12	1
Koriyama	45,739	19,684	1,882	43.0%	4,565	12,275	2,844	1,785	9
Ronyama	40,700	10,004	1,002	40.070	23.2	62.4	14.4	1,700	5
Koori	1,375	787	25	57.2%	224	467	96	24	3.
Roon	1,375	101	23	57.270	28.5	59.3	12.2	24	5.
Kuningi	1.000	550	20	E4.40/	126	343	84	22	4
Kunimi	1,022	553	20	54.1%	22.8	62.0	15.2	22	4
					88	137	41		
Tenei	728	266	17	36.5%	33.1	51.5	15.4	10	3
					1,203	2,189	584		
Shirakawa	8,567	3,976	248	46.4%	30.3	55.1	14.7	217	5.
	1				392	674	194		
Nishigo	2,856	1,260	74	44.1%	31.1	53.5	15.4	58	4
					102	221	35		
Izumizaki	893	358	6	40.1%	28.5	61.7	9.8	5	1
					215	513	153		
Miharu	1,989	881	29	44.3%	210	58.2	17.4	26	3
	1				17 657	38,639	9,321		
Subtotal	144,905	65,617	5,272	45.3%	26.9	58.9	14.2	4,992	7.

1) Those who took TUE at medical facilities outside of Fukushima Prefecture (as of May 31, 2022).

2) Upper row indicates the numbers of participants, and lower row indicates participation rate by age group.

3) Number of participants whose resident registration is not in Fukushima.

"Age" refers to the actual age at the time of the examination.

	Number of	Participanta		Participation		ticipants and par	ticipation rate	Participants reside	%
	eligible persons	Participants	Participation outside	%		by age group ²⁾		outside Fukushima	%
	а	b	Fukushima ¹⁾	b/a	8-11	12-17	18-24	c *3	c/b
Municipalities surveyed					359	1,260	2,553		
lwaki	42,505	4,172	1,301	9.8%	8.6	30.2	61.2	1,109	26.6
Sukagawa	10,704	1,429	174	13.4%	152 10.6	659 46.1	618 43.2	149	10.4
Soma	4,769	525	155	11.0%	98	233	194	164	31.2
3011a	4,709	525	155	11.076	18.7	44.4	37.0	104	51.2
Kagamiishi	1,834	226	27	12.3%	16 7.1	106 46.9	104 46.0	18	8.0
Shinchi	983	133	29	13.5%	11	58	64	26	19.5
	700	105		00.49/	8.3 7	43.6 122	48.1 36		
Nakajima	706	165	9	23.4%	4.2	73.9	21.8	6	3.6
Yabuki	2,326	650	22	27.9%	78 12.0	479 73.7	93 14.3	18	2.8
lshikawa	1,860	454	22	24.4%	29	329	96	21	4.6
	1,000			2	6.4 9	72.5 139	21.1 28		
Yamatsuri	685	176	12	25.7%	5.1	79.0	15.9	6	3.4
Asakawa	913	197	20	21.6%	71 36.0	74 37.6	52 26.4	14	7.1
Hiroto	838	216	9	25.8%	21	146	49	6	2.0
Hirata	030	210	9	20.8%	9.7	67.6	22.7	0	2.8
Tanagura	2,049	350	30	17.1%	112 32.0	152 43.4	86 24.6	26	7.4
Hanawa	1,070	286	5	26.7%	59	179	48	6	2.1
	1,010	200		20.178	20.6 38	62.6 93	16.8 16	<u> </u>	
Samegawa	457	147	4	32.2%	25.9	63.3	10.9	3	2.0
Ono	1,252	438	6	35.0%	104	287	47	5	1.1
	0.40				23.7 60	65.5 168	10.7 38		
Tamakawa	919	266	9	28.9%	22.6	63.2	14.3	5	1.9
Furudono	692	259	17	37.4%	66 25.5	140 54.1	53 20.5	7	2.7
Hinoemata	75	11	1	14.7%	3	6	2	0	0.0
					27.3 142	54.5 187	18.2 48		
Minamiaizu	1,788	377	17	21.1%	37.7	49.6	12.7	15	4.0
Kaneyama	114	23	0	20.2%	5 21.7	16 69.6	2 8.7	0	0.0
Chaura	101		2	7.0%	21.7	69.6	8.7	3	27.5
Showa	101	8	3	7.9%	25.0	50.0	25.0	3	37.5
Mishima	131	27	0	20.6%	10 37.0	14 51.9	3 11.1	0	0.0
Shimogo	646	153	2	23.7%	41	94	18	2	1.3
					26.8 50	61.4 127	11.8 182		
Kitakata	5,939	359	63	6.0%	13.9	35.4	50.7	52	14.5
Nishiaizu	618	124	4	20.1%	38 30.6	73	13 10.5	3	2.4
Tadami	475	135	5	28.4%	30.6	58.9 83	10.5	6	4.4
	410	100	5	20.4%	27.4	61.5	11.1	0	4.4
Inawashiro	1,761	501	17	28.4%	126 25.1	312 62.3	63 12.6	13	2.6
Bandai	413	95	9	23.0%	31	53	11	8	8.4
					32.6 24	55.8 55	11.6 8		
Kitashiobara	385	87	5	22.6%	27.6	63.2	9.2	4	4.6
Aizumisato	2,370	616	25	26.0%	164 26.6	337 54.7	115 18.7	23	3.7
Aizubange	2,012	503	24	25.0%	125	293	85	20	4.0
					24.9 30	58.3 60	16.9 10		
Yanaizu	393	100	3	25.4%	30.0	60.0	10.0	0	0.0
Aizuwakamatsu	15,769	1,257	293	8.0%	196 15.6	438 34.8	623 49.6	265	21.1
Viceour	454	400		07.00/	37	34.8 65	49.6 21	3	
Yugawa	451	123	3	27.3%	30.1	52.8	17.1	3	2.4
Subtotal	108,003	14,588	2,325	13.5%	2,351 16.1	6,841 46.9	5,396 37.0	2,006	13.8
T.4.1	050.005	00.005	7	0.1.70	20,008	45,480	14,717		
Total	252,908	80,205	7,597	31.7%	24.9	56.7	18.3	6,998	8.7

Implementation status of the TUE examination conducted outside Fukushima, by prefecture

As of May 31, 2022

Prefecture	Number of medical facilities	Participants	Prefecture	Number of medical facilities	Participants	Prefecture	Number of medical facilities	Participants
Hokkaido	7	185	Fukui	1	11	Hiroshima	2	15
Aomori	2	91	Yamanashi	2	64	Yamaguchi	1	13
lwate	3	172	Nagano	3	100	Tokushima	1	4
Miyagi	2	1,690	Gifu	1	13	Kagawa	1	13
Akita	1	122	Shizuoka	3	72	Ehime	1	13
Yamagata	3	339	Aichi	5	140	Kochi	1	8
lbaraki	4	456	Mie	1	17	Fukuoka	3	51
Tochigi	8	521	shiga	1	15	Saga	1	6
Gunma	2	146	Kyoto	3	47	Nagasaki	3	18
Saitama	4	426	Osaka	8	103	Kumamoto	1	19
Chiba	5	335	Hyogo	2	96	Oita	1	12
Tokyo	19	1,287	Nara	2	16	Miyazaki	1	12
Kanagawa	7	502	Wakayama	1	2	Kagoshima	1	5
Niigata	3	332	Tottori	1	2	Okinawa	1	22
Toyama	2	20	Shimane	1	11			
lshikawa	1	21	Okayama	3	32	Total	130	7,597

*The number of participants who received examination at medical facilities outside Fukushima

Appendix 3 TUE primary examination results by municipality, and grade

As of June 30, 2022


		Those with finalized results	N	umber of partici	pants by grade		Number of par		Number of partic	nants with over
	Number of	b		%			nodi	ules	Number of partic	pants with cys
	participants	%	A	1			9	6	0	6
	a	b/a	A1	A2	В	С	≥5.1mm	\leq 5.0mm	≥20.1mm	≤ 20.0mm
/unicipalities surve		0								
Kawamata	735	734	226	502	6	0	6	5	0	50
Rawamata	100	99.9	30.8	68.4	0.8	0.0	0.8	0.7	0.0	68.
Namie	728	722	237	470	15	0	15	5	0	47
		99.2	32.8	65.1	2.1	0.0	2.1	0.7	0.0	66.
litate	323	323	99	214	10	0	10	0	0	22
	-	100.0	30.7	66.3	3.1	0.0	3.1	0.0	0.0	69.
Minamisoma	3,557	3,540	1,106	2,399	35	0	35	10	0	2,42
		99.5	31.2	67.8	1.0	0.0	1.0	0.3	0.0	68.
Date	4,010	4,000	1,152	2,815	33	0	33	23	0	2,82
	+	99.8 2,215	28.8 700	70.4 1,494	0.8 21	0.0 0	0.8	0.6	0.0	70. 1,50
Tamura	2,226	99.5	31.6	67.4	0.9	0.0	0.9	0.5	0.0	67.
		194	66	124	4	0.0	4	1	0.0	12
Hirono	195	99.5	34.0	63.9	2.1	0.0	2.1	0.5	0.0	63.
		176	64	110	2.1	0.0	2.1	0.5	0.0	11
Naraha	177	99.4	36.4	62.5	1.1	0.0	1.1	0.0	0.0	63.
		417	121	291	5	0	5	1	0.0	29
Tomioka	420	99.3	29.0	69.8	1.2	0.0	1.2	0.2	0.0	70.
		82	27	55	0	0	0	0	0	5
Kawauchi	84	97.6	32.9	67.1	0.0	0.0	0.0	0.0	0.0	67
01	204	389	112	271	6	0	6	6	0	27
Okuma	391	99.5	28.8	69.7	1.5	0.0	1.5	1.5	0.0	69
Futaba	160	155	47	107	1	0	1	0	0	10
Fulapa	160	96.9	30.3	69.0	0.6	0.0	0.6	0.0	0.0	69.
Katsurao	57	57	28	29	0	0	0	0	0	2
Natsurao	51	100.0	49.1	50.9	0.0	0.0	0.0	0.0	0.0	50.
Fukushima	18,260	18,221	5,303	12,738	180	0	180	95	0	12,83
T altashirtia	10,200	99.8	29.1	69.9	1.0	0.0	1.0	0.5	0.0	70.
Nihonmatsu	3,672	3,669	1,147	2,474	48	0	48	26	0	2,50
- time time to a	0,012	99.9	31.3	67.4	1.3	0.0	1.3	0.7	0.0	68.
Motomiya	2,181	2,173	661	1,491	21	0	21	9	0	1,50
,	,	99.6	30.4	68.6	1.0	0.0	1.0	0.4	0.0	69.
Otama	676	675	196	468	11	0	11	3	0	47
	-	99.9	29.0	69.3	1.6	0.0	1.6	0.4	0.0	70.
Koriyama	19,684	19,565	5,283	14,075	207	0	207	123	0	14,20
		99.4	27.0	71.9	1.1	0.0	1.1	0.6	0.0	72.
Koori	787	786 99.9	244 31.0	533 67.8	9 1.1	0 0.0	9 1.1	<u> </u>	0.0	54 68.
		552	179	366	7	0.0	7	2	0.0	37
Kunimi	553	99.8	32.4	66.3	1.3	0.0	1.3	0.4	0.0	67.
		263	75	183	5	0.0	5	0.4	0.0	18
Tenei	266	98.9	28.5	69.6	1.9	0.0	1.9	0.0	0.4	70.
		3,940	1,101	2,802	37	0.0	37	23	0.4	2,82
Shirakawa	3,976	99.1	27.9	71.1	0.9	0.0	0.9	0.6	0.0	71
NP 1 1	4 000	1,252	371	864	17	0	17	5	0	87
Nishigo	1,260	99.4	29.6	69.0	1.4	0.0	1.4	0.4	0.0	69
	0.55	356	106	246	4	0	4	2	0	24
Izumizaki	358	99.4	29.8	69.1	1.1	0.0	1.1	0.6	0.0	69
N 411-	00.1	879	239	631	9	0	9	6	0	63
Miharu	881	99.8	27.2	71.8	1.0	0.0	1.0	0.7	0.0	72
Culture	65.047	65,335	18,890	45,752	693	0	693	357	1	46,14
Subtotal	65,617	99.6	28.9	70.0	1.1	0.0	1.1	0.5	0.0	70


	Number of	Those with finalized results . b	Ν	lumber of partic		e	Number of pa nod	rticipants with ules	Number of partic	ipants with cysts
	participants	% b/a	A A1		В	с	≥5.1mm	% ≤ 5.0mm	≥20.1mm	6 ≤ 20.0mm
Municipalities survey		1								
Iwaki	4,172	4,134	1,293	2,745	96	0	96	36	0	2,786
	,	99.1	31.3	66.4	2.3	0.0	2.3	0.9	0.0	67.4
Sukagawa	1,429	1,386 97.0	416 30.0	943 68.0	27 1.9	0.0	27 1.9	19 1.4	0.0	956 69.0
		524	176	334	1.5	0.0	1.5	1.4	0.0	346
Soma	525	99.8	33.6	63.7	2.7	0.0	2.7	0.2	0.0	66.0
Kagamiishi	226	220	57	157	6	0	6	1	0	160
Ragannion	220	97.3	25.9	71.4	2.7	0.0	2.7	0.5	0.0	72.7
Shinchi	133	133	35	94	4	0	4	2	0	96
		100.0 87	26.3 29	70.7 57	3.0 1	0.0	3.0 1	1.5 2	0.0	72.2 58
Nakajima	165	52.7	33.3	65.5	1.1	0.0	1.1	2.3	0.0	66.7
Mahadal	050	286	95	188	3	0	3	0	0	189
Yabuki	650	44.0	33.2	65.7	1.0	0.0	1.0	0.0	0.0	66.1
Ishikawa	454	189	57	128	4	0	4	2	0	131
	101	41.6	30.2	67.7	2.1	0.0	2.1	1.1	0.0	69.3
Yamatsuri	176	78	15	60	3	0	3	1	0	63
		44.3 120	19.2 41	76.9 77	3.8	0.0	3.8 2	1.3	0.0	80.8 78
Asakawa	197	60.9	34.2	64.2	1.7	0.0	1.7	2.5	0.0	65.0
		107	38	65	4	0.0	4	2.5	0.0	68
Hirata	216	49.5	35.5	60.7	3.7	0.0	3.7	0.9	0.0	63.6
Tanagura	350	250	71	173	6	0	6	0	0	176
Tanagura	330	71.4	28.4	69.2	2.4	0.0	2.4	0.0	0.0	70.4
Hanawa	286	92	21	67	4	0	4	0	0	69
		32.2	22.8	72.8	4.3	0.0	4.3	0.0	0.0	75.0
Samegawa	147	53 36.1	17 32.1	35 66.0	1 1.9	0.0	1 1.9	1.9	0.0	36 67.9
		175	54	119	1.9	0.0	2	1.9	0.0	121
Ono	438	40.0	30.9	68.0	1.1	0.0	1.1	1.1	0.0	69.1
	266	79	22	53	4	0	4	1	0	56
Tamagawa	266	29.7	27.8	67.1	5.1	0.0	5.1	1.3	0.0	70.9
Furudono	259	87	22	64	1	0	1	2	0	65
		33.6	25.3	73.6	1.1	0.0	1.1	2.3	0.0	74.7
Hinoemata	11	2	50.0	1	0	0	0	0	0	50.0
		18.2 89	50.0 25	50.0 62	0.0	0.0	0.0	0.0	0.0	50.0 63
Minamiaizu	377	23.6	28.1	69.7	2.2	0.0	2.2	1.1	0.0	70.8
		7	3	4	0	0.0	0	0	0.0	4
Kaneyama	23	30.4	42.9	57.1	0.0	0.0	0.0	0.0	0.0	57.1
Showa	8	5	3	2	0	0	0	0	0	2
	, · · ·	62.5	60.0	40.0	0.0	0.0	0.0	0.0	0.0	40.0
Mishima	27	5	1	3	1	0	1	0	0	4
		18.5	20.0	60.0	20.0	0.0	20.0	0.0	0.0	80.0
Shimogo	153	25 16.3	11 44.0	13 52.0	4.0	0.0	1 4.0	4.0	0.0	13 52.0
		316	96	207	13	0.0	13		0.0	216
Kitakata	359	88.0	30.4	65.5	4.1	0.0	4.1	1.6	0.0	68.4
Nishiaizu	124	30	9	20	1	0	1	0	0	21
i visi ilai2U	124	24.2	30.0	66.7	3.3	0.0	3.3	0.0	0.0	70.0
Tadami	135	33	10	23	0	0	0	1	0	23
		24.4	30.3	69.7	0.0	0.0	0.0	3.0	0.0	69.7
Inawashiro	501	417 83.2	126 30.2	285 68.3	6 1.4	0.0	6 1.4	2	0.0	288 69.1
		63.2 49	<u> </u>	33	1.4	0.0	1.4	0.5	0.0	33
Bandai	95	51.6	30.6	67.3	2.0	0.0	2.0	0.0	0.0	67.3
Kitashiobara	87	18	9	9	0	0	0	0	0	9
RIGONICENT	0/	20.7	50.0	50.0	0.0	0.0	0.0	0.0	0.0	50.0
Aizumisato	616	271	87	179	5	0	5	2	0	181
		44.0	32.1	66.1	1.8	0.0	1.8	0.7	0.0	66.8
Aizubange	503	123	31 25.2	89 72.4	3	0	3	3	0	90 73-2
		24.5 13	25.2 5	72.4 8	2.4 0	0.0	2.4 0	2.4	0.0	73.2
Yanaizu	100	13.0	38.5	61.5	0.0	0.0	0.0	0.0	0.0	61.5
	4.057	1,104	362	712	30	0	30	14	0	731
	1,257	87.8	32.8	64.5	2.7	0.0	2.7	1.3	0.0	66.2
Aizuwakamatu			0	17	1	0	1	1	0	18
	102	26	8							
Aizuwakamatu Yugawa	123	21.1	30.8	65.4	3.8	0.0	3.8	3.8	0.0	69.2
	123 14,588	21.1 10,533	30.8 3,261	65.4 7,026	246	0	246	104	0	7,159
Yugawa		21.1 10,533 72.2	30.8 3,261 31.0	65.4 7,026 66.7	246 2.3	0 0.0	246 2.3	104 1.0	0.0	7,159 68.0
Yugawa		21.1 10,533	30.8 3,261	65.4 7,026	246	0	246	104	0	7,159

1 TUE primary examination results by age and sex


As of June 30, 2022

															(Person)
Grade Sex	A			Α2			В		С			合計			
Age group	Male	A1 Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
8-11	2,990	2,562	5,552	6,613	6,494	13,107	16	29	45	0	0	0	9,619	9,085	18,704
12-17	6,375	5,410	11,785	14,984	15,355	30,339	143	300	443	0	0	0	21,502	21,065	42,567
18-24	2,216	2,598	4,814	4,229	5,103	9,332	130	321	451	0	0	0	6,575	8,022	14,597
Total	11,581	10,570	22,151	25,826	26,952	52,778	289	650	939	0	0	0	37,696	38,172	75,868







Results by age group (Female)



2. Nodule characteristics


Na dula aima	Tatal			Grade		
Nodule size	Total	Male	Female			
None	74,468	37,244	37,224	A1	98.2%	
≦3.0mm	63	18	45	A2	0.6%	
3.1-5.0mm	398	145	253	AZ	0.0%	
5.1-10.0mm	603	191	412			
10.1-15.0mm	192	52	140		1.2%	
15.1-20.0mm	85	30	55	В		
20.1-25.0mm	27	7	20			
≧25.1mm	32	9	23			
Total	75,868	37,696	38,172			






3 Cyst characteristics

Cyst size	Total			Grade		
Cyst size	Total	Male	Female	Olade		
None	22,566	11,726	10,840	A1	69.1%	
≤3.0mm	29,867	15,674	14,193		00.170	
3.1 - 5.0mm	19,946	9,075	10,871			
5.1 - 10.0mm	3,404	1,204	2,200	A2	00.00/	
10.1 - 15.0mm	73	16	57		30.9%	
15.1 - 20.0mm	11	1	10			
20.1 - 25.0mm	0	0	0	В	0.001%	
≥25.1mm	1	0	1	D	0.00176	
Total	75,868	37,696	38,172			





Surgery cases for malignancy or suspicion of malignancy

1. Municipalities surveyed in FY2020		
Malignant or suspicious for malignancy:	18	(Surgery cases: 5, Papillary thyroid carcinoma: 5)
2. Municipalities surveyed in FY2021		
Malignant or suspicious for malignancy:	5	(Surgery cases: 2, Papillary thyroid carcinoma: 2)
3. Total		
Malignant or suspicious for malignancy:	23	(Surgery cases: 7, Papillary thyroid carcinoma: 7)